China SXT Pharmaceuticals (SXTC) Current Leases (2023 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Current Leases for 4 consecutive years, with $67979.0 the latest figure, recorded in Q1 2026.

• Quarterly Current Leases rose 11.02% year-over-year to $67979.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67979.0 (up 11.02% YoY) and the FY2026 annual result came in at $67979.0, up 11.02% from the prior year.
• Current Leases advanced to $67979.0 in Q1 2026 per SXTC's latest filing, from $64118.0 in the prior quarter.
• Over the last five years, Current Leases for SXTC reached as high as $67979.0 in Q1 2026 and fell as low as $56171.0 in Q3 2023.
• A 4-year average of $61430.6 and a median of $61229.0 in 2025 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases grew 14.15% — and 2025, when it changed 0.0%.
• Year by year, Current Leases stood at $56171.0 in 2023, then increased by 14.15% to $64118.0 in 2024, then changed by 0.0% to $64118.0 in 2025, then climbed by 6.02% to $67979.0 in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $67979.0, $64118.0, and $61229.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.